Insulet first launched its Omnipod 5 patch-pump for people with Type 1 diabetes in 2022. Now, the device is also indicated for people with Type 2 diabetes ages 18 years and older. There are roughly 6 ...

Diabetes is a chronic health condition affecting blood glucose levels. In some cases, it requires constant management in the form of monitoring blood glucose levels and administering insulin.

Insulet’s Omnipod 5 with the Dexcom G6 CGM. [Image from Insulet] JAMA today published outcomes from a study evaluating the safety and efficacy of the Insulet Omnipod 5 in adults with type 2 diabetes.

The Omnipod 5 with the Abbott FreeStyle Libre 2 Plus. [Image courtesy of Insulet] Insulet (Nasdaq:PODD) today announced positive results from a clinical trial pitting its Omnipod 5 against ...

On the heels of launching Omnipod 5 in the United States, Insulet has received CE marking to sell the device in Europe. The Omnipod 5 is the first CE marked tubeless hybrid closed loop system (also ...

Insulet’s Omnipod 5 is cleared by the US FDA and has a European CE mark for use in patients aged two years and older with type 1 diabetes. Image Credit: ivector / Shutterstock. Insulet is looking to ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the leader in tubeless insulin pump technology with its Omnipod ® Insulin Management System (Omnipod System) ...

Insulet Corporation PODD announced favorable RADIANT trial clinical data for its Omnipod 5 at the 18th International Conference on Advanced Technologies and Treatments for Diabetes (“ATTD”). Omnipod 5 ...

The Omnipod 5 Automated Insulin Delivery System is now commercially available in Australia, launching soon in Belgium, Canada, and Switzerland. Omnipod 5 is now commercially available in Australia ...

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod ® brand of products, today announced ...